Abstract:Abstract 3065 Introduction: Current studies suggest that monitoring the minimal residual disease (MRD) of patients with malignant hematological disease after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is helpful for screening patients at high risk of relapse. WT1 and leukemia-associated aberrant immune phenotypes (LAIPs) were the major MRD parameters used to predict leukemia relapse after allo-HSCT. The aim of this study was to first evaluate the clinical value of various positive MRD standards for accurately predicting relapse based on WT1 and flow cytometry (FCM) data in a large sample of adult patients with actue leukemia (AL) in a single transplant center. Methods: In total, 824 AL patients treated with non-T-cell-depleted allo-HSCT at the Peking University Institute of Hematology from January 1, 2006 to November 30, 2011 were enrolled in this study. BM samples from patients were obtained at regular time points: +1 month, +2 months, +3 months, +4.5 months, +6 months, +9 months, +12 months and every 6 months thereafter for the MRD investigation after HSCT. WT1 expression was evaluated using TaqMan-based RQ-PCR technology and LAIPs were detected using 4/7-color FCM. At least one positive MRD marker, including WT1 or LAIP, was detected before transplantation in 90.8% (748 of 824) of the subjects. Positive FCM could be found in all 748 patients. Both FCM+ and WT1+ were detected before transplantation in 58.7% (484/824) of subjects. We compared the sensitivity and specificity of diverse, multiple-criteria MRD forecasting standards including one WT1+, two consecutive WT1+, one FCM+, two consecutive FCM+, concurrent WT1+ & FCM+, concurrent WT11.0+ & FCM+, MRDco+ and MRDco1.0+, based on WT1 and FCM assays. Results: Higher sensitivity was achieved without a loss of specificity in total 824 patients as well as in 748 patients with WT1+ or FCM+ before transplant when MRDco+ was used as the positive MRD standard (Table 1). Similar results were observed, even in 484 patients with acute myeloid leukemia (AML, n=308) and acute lymphoblastic leukemia (ALL, n=176) who had both abnormal WT1 and LAIPs values before transplant (Table 1). A multivariate analysis that included age, sex, disease status (CR1/CR2), donor type, number of chemotherapy courses before CR1, and MRD status (including the different MRD standards mentioned above) after transplantation showed that MRDco+ was an independent risk factor to predict leukemia relapse after allo-HSCT; it had the most powerful contribution to leukemia recurrence after transplant in both AML (HR=12.54, 95% CI: 7.01–22.42, P<0.001) and ALL (HR=12.84, 95% CI: 6.05–27.25, P<0.001) compared with other MRD standards. Conclusions: The combined use of FCM and WT1 monitoring were able to distinguish between patients with low and high risk of relapse. Diverse standards of positive MRD raised in this work were conductive to guide different interventive measures. Further studies should focus on exploring the new better parameters with both high sensitivity and specificity in predicting the recurrence of leukemia after allo-HSCT. Disclosures: No relevant conflicts of interest to declare.

Application of Flow Cytometry in Detection of Minimal Residual Disease in Hematopoietic Stem Cell Transplantation for Patients with Acute Leukemia

Minimal residual disease level determined by flow cytometry provides reliable risk stratification in adults with T-cell acute lymphoblastic leukaemia

[Detecting minimal residual disease status in allogeneic hematopoietic stem cell transplantation of patients with high-risk acute leukemia].

Different Minimal Residual Disease Levels Between Childhood Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia Detected with Multi-Parameter Flow Cytometry.

[Clinical Significance of Minimal Residual Disease Monitoring by Multi-parameter Flow Cytometry before Allogeneic Hematopoietic Stem Cell Transplantation for Prognosis of Acute Leukemia Patients].

The Clinical Significane of Detecting Minimal Residual Disease with Acute Myeloid Leukemia by Flow Cytometry

Clinical Implication of Minimal Residue Disease Monitoring by WT1 Gene Detection and Flow Cytometry in Myelodysplastic Syndrome with Allogeneic Stem Cell Transplantation

Pretransplantation minimal residual disease monitoring by multiparameter flow cytometry predicts outcomes of AML patients receiving allogeneic hematopoietic stem cell transplantation

Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation

The Prognostic Value of Early Detection of Minimal Residual Disease As Defined by Flow Cytometry and Gene Mutation Clearance for Myelodysplastic Syndrome Patients after Myeloablative Allogeneic Hematopoietic Stem-Cell Transplantation.

Minimal Residual Disease Status At Day+100 Post Allogeneic Hematopoietic Stem Cell Transplantation Is A Powerful Predictor For Post-Transplant Outcome In Patients With High Risk Acute Leukemia

Detection of minimal residual disease by flow cytometry as a useful approach for predicting relapse in childhood B-lingeage acute lymphoblastic leukemia

Prognostic Significance of Flow Cytometric Minimal Residual Disease Assessment after the First Induction Course in Chinese Childhood Acute Myeloid Leukemia

Combined Use of WT1 and Flow Cytometry Monitoring Can Promote Sensitivity of Predicting Relapse after Allogeneic HSCT Without Affecting Specificity.

Detection of the Minimal Residual Disease of 53 Cases with Acute Myelocyte Leukemia by Flow Cytometry

Effect of Minimal Residual Disease Monitoring by Multiparameter Flow Cytometry Pre-Conditioning on Prognosis of Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation

Clinical significance of minimal residual disease detection by multi-parameter flow cytometry during induction therapy in acute myeloid leukemia

Predictable recurrence by regular monitoring minimal residual disease with flowcytometry in the patients with acult leukemia: a single-center study of 163 cases

Significance of WT1 and multiparameter flow cytometry assessment in patients with chronic myelomonocytic leukemia receiving allogeneic hematopoietic stem cell transplantation

Impact of Pre-Transplantation Minimal Residual Disease Determined by Multiparameter Flow Cytometry on the Outcome of AML Patients with FLT3-ITD after Allogeneic Stem Cell Transplantation.

Association of Persistent Minimal Residual Disease with Poor Outcomes of Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation